Diasorin S.p.a. · MIL:DIA
Diasorin — H1 2024 Earnings Presentation
18 slides from Diasorin's earnings presentation, Jul 29, 2024
Slide 1: H1 2024 Results
XS Oiasorin H1 2024 RESULTS July 29, 2024
Slide 2: Disclaimer
DISCLAIMER In General. This disclaimer applies to this presentation and any oral No distribution of this Presentation. This Presentation is being furnished to comments of any person presenting it. This document, taken together you solely for your information and may not be reproduced, in whole or in
Slide 3: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which Diasorin operates and the beliefs and assumptions of the management of Diasorin. In addition, the management of Dias
Slide 4: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 5: Financial Highlights
FINANCIAL HIGHLIGHTS Change Change Data in €/mln Q2 2024 H1 2024 @ current @ CER @ current @ CER Revenues 300 +5% +4% 589 +2% +2% Immunodiagnostics ex-COVID 205 +12% +11% 391 +10% +10% Molecular Diagnostics ex-COVID 49 +6% +5% 100 +4% +4% Licensed Technologies1 41 -6% -7% 84 -2% -2% COVID 5 -60% -60
Slide 6: H1 2024 Key Facts
H1 2024 KEY FACTS PRODUCT & BUSINESS DEVELOPMENT IMMUNODIAGNOSTICS • LIAISON® LymeDetect® submitted to the U.S. FDA MOLECULAR DIAGNOSTICS • Execution of the project to sunset the ARIES molecular diagnostics platform and to consolidate the related customer base on the Diasorin LIAISON® MDX platform •
Slide 7: Managerial Outlook on Q2 and H1 2024 Revenues
MANAGERIAL OUTLOOK ON Q2 AND H1 2024 REVENUES Q2 2024 Group revenues (data in €/mln) H1 2024 Group revenues (data in €/mln) Data @CUR Data @CER Data @CUR Data @CER +5% +4% +2% +2% 287 300 287 299 576 589 576 590 5 5 14 14 13 41 13 41 35 35 COVID sales 84 84 44 44 85 85 49 49 100 101 Licensed 46 46 9
Slide 8: Q2 and H1 2024 Revenues by Geography
Q2 AND H1 2024 REVENUES BY GEOGRAPHY Q2 2023 Q2 2024 Rest of the World 18% Rest of the World 16% North America North America Direct Direct 48% 49% Europe Direct Europe Direct 35% 34% H1 2023 H1 2024 Rest of the World Rest of the World 16% 15% North America North America Direct Direct 49% 49% Europe
Slide 9: Q2 and H1 2024 Profitability Profile
Q2 AND H1 2024 PROFITABILITY PROFILE (data in €/mln @ current exchange rates) 32% 34% 287 300 92 102 Net Revenues H1 2024 Adjusted2 EBITDA margin expansion was driven by a Adjusted2 combination of increased Gross Margin (resulting from higher EBITDA Q2 2023 Q2 2024 volumes and favorable mix) and eff
Slide 10: FY 2024 Company Guidance
FY 2024 COMPANY GUIDANCE
Slide 11: Company Revises FY 2024 Guidance Upwards
COMPANY REVISES FY 2024 GUIDANCE UPWARDS UPGRADED FY 2024 COMPANY GUIDANCE (@CER) Ex-COVID revenues: +6% / +7% (COVID sales equal to ~ 30 €/mln) Adjusted2 EBITDA Margin: ~ 33% PREVIOUS FY 2024 COMPANY GUIDANCE (@CER) Ex-COVID revenues: +5% / +7% (COVID sales equal to ~ 30 €/mln) Adjusted2 EBITDA Mar
Slide 12: Financial Schemes
FINANCIAL SCHEMES
Slide 13: Income Statement
INCOME STATEMENT Q2 H1 (Amounts in million of euros) 2023 2024 2023 2024 Net Revenues 287 300 576 589 Cost of sales (100) (102) (198) (199) Gross profit 187 198 379 390 65% 66% 66% 66% Sales and marketing expenses (69) (71) (142) (141) Research and development costs (23) (21) (46) (43) General and a
Slide 14: Balance Sheet
BALANCE SHEET Amounts in million of euros 12/31/2022 12/31/2023 Change Goodwill and intangibles assets 1,925 1,985 +60 Property, plant and equipment 256 266 +9 Other non-current assets 35 34 -0 Net working capital 369 386 +17 Other non-current liabilities (270) (275) -4 Net Invested Capital 2,314 2,
Slide 15: Cash Flow Statement
CASH FLOW STATEMENT Q2 H1 Amounts in million of euros 2023 2024 2023 2024 Cash and cash equivalents at the beginning of the period 373 308 242 280 Cash provided by operating activities 104 80 146 155 Cash provided/(used) in investing activities 86 (50) 108 (11) Cash provided/(used) in financing acti
Slide 16: H1 2024 Reconciliation to Consolidated Financial Statements
H1 2024 RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS (amounts in million of Euro) Gross profit EBITDA EBIT Net result IFRS Financial Statements Measures 390 196 132 96 % on Revenues 66% 33% 22% 16% Adjustments “One-off” costs related to the integration and restructuring of Luminex - 2 2 2 Dep
Slide 17: H1 2023 Reconciliation to Consolidated Financial Statements
H1 2023 RECONCILIATION TO CONSOLIDATED FINANCIAL STATEMENTS (amounts in million of Euro) Gross profit EBITDA EBIT Net result IFRS Financial Statements Measures 379 182 117 87 % on Revenues 66% 32% 20% 15% Adjustments “One-off” costs related to the integration and restructuring of Luminex - 8 8 8 Dep
Slide 18: DOIASORIN
>) DOiasorin 2 (9 Diasorin, Chicago